{"url_path":"/sec/mdgl/8-k/2026-06-17/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-17","source_url":"https://www.sec.gov/Archives/edgar/data/1157601/0001104659-26-075130-index.html","accession_number":"0001104659-26-075130","cik":"0001157601","ticker":"MDGL","issuer_name":"MADRIGAL PHARMACEUTICALS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1157601/0001104659-26-075130-index.html","primary_entity_key":"0001157601","primary_entity_name":"MADRIGAL PHARMACEUTICALS, INC."},"word_count":104,"has_tables":true,"body_markdown":"**Item 9.01 Financial Statements and Exhibits.**\n\n \n\n(d) Exhibits\n\n \n\n**Exhibit** **** **Number**\n \n**Description**\n\n \n \n \n\n[10.1](tm2617490d2_ex10-1.htm)\n \n[Madrigal Pharmaceuticals, Inc. 2026 Stock Plan](tm2617490d2_ex10-1.htm)\n\n \n \n \n\n[10.2](tm2617490d2_ex10-2.htm)\n \n[Madrigal Pharmaceuticals, Inc. 2026 Employee Stock Purchase Plan](tm2617490d2_ex10-2.htm)\n\n \n \n \n\n[10.3](tm2617490d2_ex10-3.htm)\n \n[Madrigal Pharmaceuticals, Inc. Nonqualified Deferred Compensation Plan](tm2617490d2_ex10-3.htm)\n\n \n \n \n\n104\n \nCover Page Interactive Data File (embedded within the Inline XBRL Document)\n\n \n\n4\n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant to the requirements of the Securities\nExchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n**MADRIGAL PHARMACEUTICALS, INC.**\n\n \n \n \n\n \nBy:\n/s/\nMardi C. Dier\n\n \n \nName: Mardi C. Dier\n\n \n \nTitle: Executive Vice President\nand Chief Financial Officer\n\nDate: June 17, 2026\n \n \n\n \n\n5"}